Navigation Links
Ohio's Bioscience Industry Ranks Among Top in the Nation

Business Facilities Magazine Ranks Ohio 4th in Nation for Bioscience


COLUMBUS, Ohio, July 30 /PRNewswire/ -- Ohio ranks best in the Midwest and 4th in the nation for its strengths in the bioscience industry according to a new report released by Business Facilities Magazine. The report ranks states based on their number of bioscience facilities, R&D funding, venture capital investments, employment, bioscience-targeted tax exemptions, university grant funding and higher education degrees.

(LOGO: )

According to the Ohio Business Development Coalition, the nonprofit organization that markets the state for capital investment, the report reinforces Ohio's standing as a national leader in the bioscience industry.

"Ohio has created an ideal environment for establishing and growing a bioscience business," said Tony Dennis, president and CEO of BioOhio, a non- profit organization designed to build and accelerate bioscience industry, research and education in Ohio. For businesses, the benefit is a critical mass of like-minded bio-businesses and research universities, and a highly qualified workforce. For executives, the state's vast educational and recreational opportunities make Ohio particularly attractive both professionally and personally."

The report's authors concluded, "every state that placed in the top 10 of this year's ranking should be considered a biotechnology leader."

As of December 2007, Ohio's total bioscience entities grew to at least 818. Capital investments, which topped $1 billion in 2006 alone, accelerated Ohio's bioscience growth by nearly $100 million, or eight percent, compared to 2005.

Based on the color model established by European bioscience leaders, Ohio's strength in the Red (health), Green (agriculture) and White (industrial) bioscience industry sectors stimulates innovation, promotes cross-collaboration and provides cost-effective solutions to scientific challenges.

One of the most significant initiatives supporting Ohio's bioscience industry is the state's Third Frontier Project, a 10-year, $1.6 billion initiative to help catalyze connections between companies and academia. The project is the state's largest-ever commitment to expanding high-tech research capabilities and promoting innovation and company formation that will create high-paying jobs for generations to come.

Between January 2002 and June 2007, $637 million of Ohio's Third Frontier Project funds had been competitively awarded, of which 55 percent supported bioscience-related development and commercialization initiatives. According to the Ohio Department of Development, this state investment has led to an additional $2.7 billion in cost share and leveraged co-investment into Ohio while creating or retaining 4,850 jobs.

"Business leaders are realizing how, in Ohio, they're able to find a perfect balance between successfully growing a business and still enjoying life," said Ed Burghard, executive director of the Ohio Business Development Coalition. "Business owners profit from the bottom-line benefits of better work-life balance for their employees. Ohio offers low-cost, low stress communities in a combination of micropolitan and metropolitan cities. This diversity provides executives and employees the resources and time to make any ambition achievable. Ohio truly is the state of perfect balance."

About the Ohio Business Development Coalition

The Ohio Business Development Coalition (OBDC) is a nonprofit organization that markets the state for capital investment. The OBDC provides marketing strategy and implementation to support Ohio's economic development efforts. For more information on business development or business relocation, visit .

To view the complete report, visit .

Media Contact: Dace de la Foret

Paul Werth Associates

614-224-8114, ext. 235

SOURCE Ohio Business Development Coalition
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
2. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
3. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
4. SuperArray Bioscience Changes Name to SABiosciences and Moves Into New Larger Facility on Verge of Tenth Anniversary
5. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
6. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
7. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
8. PURE Bioscience Announces Distribution Agreement With Orchem Corporation
9. Pacific Biosciences Raises $100 Million to Fund Commercial Product Development
10. PURE Bioscience CEO to Ring NASDAQ Closing Bell
11. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):